Heron Therapeutics (NASDAQ:HRTX – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Heron Therapeutics to related businesses based on the strength of its institutional ownership, dividends, valuation, earnings, analyst recommendations, profitability and risk.
Profitability
This table compares Heron Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heron Therapeutics | -14.55% | -277.36% | -8.76% |
| Heron Therapeutics Competitors | -2,398.26% | -203.62% | -15.08% |
Institutional and Insider Ownership
80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Heron Therapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heron Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
| Heron Therapeutics Competitors | 7845 | 13797 | 25812 | 1039 | 2.41 |
Heron Therapeutics currently has a consensus target price of $2.00, indicating a potential upside of 545.16%. As a group, “Pharmaceuticals” companies have a potential upside of 23.56%. Given Heron Therapeutics’ higher possible upside, equities research analysts clearly believe Heron Therapeutics is more favorable than its peers.
Risk and Volatility
Heron Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Heron Therapeutics’ peers have a beta of -0.04, suggesting that their average share price is 104% less volatile than the S&P 500.
Earnings & Valuation
This table compares Heron Therapeutics and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Heron Therapeutics | $148.22 million | -$20.19 million | -2.58 |
| Heron Therapeutics Competitors | $18.55 billion | $3.23 billion | 562.96 |
Heron Therapeutics’ peers have higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
Heron Therapeutics peers beat Heron Therapeutics on 8 of the 13 factors compared.
About Heron Therapeutics
Heron Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for patients in acute care settings, including cancer treatment and surgery. Its work includes medicines intended to prevent nausea and vomiting associated with chemotherapy and surgery, as well as treatments for postsurgical pain. Heron’s products include CINVANTI and APONVIE, injectable formulations of aprepitant used to help prevent nausea and vomiting in specified clinical settings. The company also developed ZYNRELEF, a combination of bupivacaine and meloxicam for postsurgical pain, and SUSTOL, an extended-release formulation of granisetron for chemotherapy-related nausea and vomiting.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
